Highlights eFFECTOR Therapeutics, Inc.

Equities

EFTR

US28202V2079

Delayed Nasdaq Other stock markets 10:33:20 09/05/2024 pm IST			5-day change	1st Jan Change
2.02 ^USD	-2.88%		-6.48%	-82.71%

04/04	Health Care Down on Retreat From Risk -- Health Care Roundup	DJ
04/04	Top Midday Decliners	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Health Care Down on Retreat From Risk -- Health Care Roundup	05/04	DJ
Top Midday Decliners	04/04	MT
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	04/04	CI
Top Premarket Decliners	26/03	MT
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	26/03	CI
EFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients	08/12	CI
EFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer	28/11	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Effector Therapeutics, Inc. Announces Initiation of Dosing in an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Relapsed/Refractory Acute Myeloid Leukemia	24/23/24	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Debt Talks Progress Lift Exchange-Traded Funds, Equity Futures Pre-Bell Friday	26/23/26	MT
EFFECTOR Reports 'Positive' Data Updates in Mid-Stage Breast Cancer Trial; Shares Soar After-Hours	26/23/26	MT
EFFECTOR Therapeutics, Inc. Announces Positive Interim Data Updates from Phase 2 Expansion Cohort Evaluating Zotatifin Combined with Fulfvestrant and Abemaciclib	26/23/26	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10	CI
EFFECTOR Therapeutics, Inc. to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer	11/23/11	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	09/23/09	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	09/23/09	CI
EFFECTOR Therapeutics, Inc. Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID	21/23/21	CI
EFFECTOR Therapeutics, Inc. Provides Positive Clinical Data Update for Zotatifin and General Corporate Update	06/23/06	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	08/22/08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights eFFECTOR Therapeutics, Inc.

Equities

EFTR

US28202V2079

Highlights

Filters